首页> 外文期刊>P & T: a peer-reviewed journal for formulary management >Novel Treatment of Allergic Asthma and Seasonal Allergic Rhinitis: Focus on Omalizumab (Xolair??) | P&T Community

【24h】

Novel Treatment of Allergic Asthma and Seasonal Allergic Rhinitis: Focus on Omalizumab (Xolair??) | P&T Community

机译：过敏性哮喘和季节性过敏性鼻炎的新型治疗：专注于奥马珠单抗（Xolair ??） P＆T社区

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《P & T: a peer-reviewed journal for formulary management》 |2002年第11期|共页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Omalizumab (Xolair) in children with seasonal allergic rhinitis: Leukotriene release as a potential in vitro parameter to monitor therapeutic effects. [J] . Kopp MV, Stenglein S, Kamin W, Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology . 2007,第6期

机译：奥马珠单抗（Xolair）在季节性过敏性鼻炎患儿中：白三烯释放是监测治疗效果的潜在体外参数。
2. Self-assessment of Allergic Rhinitis and Asthma (SACRA) Questionnaire-based Allergic Rhinitis Treatment Improves Asthma Control in Asthmatic Patients with Allergic Rhinitis [J] . Masanori Yasuo, Yoshiaki Kitaguchi, Yoshimichi Komatsu, Internal medicine. . 2017,第1期

机译：过敏性鼻炎和哮喘的自我评估（SACRA）基于问卷的过敏性鼻炎治疗可改善哮喘性变应性鼻炎患者的哮喘控制
3. Omalizumab: Treatment of allergic rhinitis treatment of asthma [J] . Cullell Young M, Bayes M, Leeson PA Drugs of the Future . 2002,第6期

机译：奥马珠单抗：治疗过敏性鼻炎治疗哮喘
4. Treatment Implications of Co-Existing Asthma, Allergic Rhinitis and Gastroesophageal Reflux [C] . P Greenberger World Asthma COPD Forum . 2009

机译：共存哮喘，过敏性鼻炎和胃食管反流的治疗意义
5. The impact of nasal congestion and rural residence on pulmonary function and asthma control in adults with asthma and allergic rhinitis. [D] . Hogan, Donna Grace. 2011

机译：鼻充血和农村居民对哮喘和过敏性鼻炎成人的肺功能和哮喘控制的影响。
6. Self-assessment of Allergic Rhinitis and Asthma (SACRA) Questionnaire-based Allergic Rhinitis Treatment Improves Asthma Control in Asthmatic Patients with Allergic Rhinitis [O] . Masanori Yasuo, Yoshiaki Kitaguchi, Yoshimichi Komatsu, 2017

机译：过敏性鼻炎和哮喘的自我评估（SACRA）基于问卷的过敏性鼻炎治疗可改善哮喘性变应性鼻炎患者的哮喘控制
7. PRS30 Identifying the Patient Population Where Treatment of Severe Allergic Asthma with Omalizumab (XOLAIR®) Exhibits Optimal Cost-Effectiveness in Australia [O] . Tilden D., Cottrell S., Tocchini L., 2011

机译：PRS30识别使用奥马珠单抗（XOLAIR®）治疗严重过敏性哮喘在澳大利亚具有最佳成本效益的患者人群

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号